Oral composition for perimenopause
Compositions and methods are disclosed for treating one or more symptoms of perimenopause. A composition includes a cannabidiol, a Curcuma longa extract, and/or a Lepidium meyenii extract. A method of manufacturing a composition comprises including a cannabidiol, a Curcuma longa extract, and/or a Lepidium meyenii extract in the composition. A method of administering a composition includes administering a cannabidiol, a Curcuma longa extract, and/or a Lepidium meyenii extract of the composition.
1 . A composition comprising:
one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, comprising:
a cannabidiol comprising between about 0.1% and 5% of the composition, by weight;
a Curcuma longa extract prepared with a dispersing agent comprising a carrier oil, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight;
a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight;
a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight:
a Schisandra chinensis extract comprising between about 1% and 20% of the composition, by weight; and
a Cinnamomum verum extract comprising between about 1% and 7% of the composition, by weight.
2 . The composition of claim 1 , wherein the Schisandra chinensis extract comprises a Schisandra chinensis fruit powder.
3 . The composition of claim 2 , wherein the Schisandra chinensis extract comprises between 1% and 10% of the composition, by weight.
4 . The composition of claim 1 , wherein the Cynara scolymus extract comprises between 1% and 20% of the composition, by weight.
5 . The composition of claim 1 , wherein the Withania somnifera extract comprises between 10% and 30% of the composition, by weight.
6 . The composition of claim 5 , wherein the Withania somnifera extract comprises a Withania somnifera root extract powder.
7 . The composition of claim 1 , wherein the Lepidium meyenii extract comprises between 10% and 20% of the composition, by weight.
8 . The composition of claim 1 , wherein the Cinnamomum verum extract comprises a Cinnamomum verum bark powder.
9 . The composition of claim 1 , further comprising microcrystalline cellulose, wherein the microcrystalline cellulose comprises between 0.1% and 3% of the composition, by weight.
10 . The composition of claim 1 , further comprising xanthan gum, wherein the xanthan gum comprises between 0.1% and 3% of the composition, by weight.
11 . The composition of claim 1 , further comprising magnesium stearate, wherein the magnesium stearate comprises between 0.01% and 2% of the composition, by weight.
12 . A method of manufacturing a composition, the method comprising:
manufacturing a composition comprising one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, the composition further comprising:
a cannabidiol comprising between about 0.1% and 5% of the composition, by weight;
a Curcuma longa extract prepared with a dispersing agent comprising a carrier oil, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight;
a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight:
a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight;
a Schisandra chinensis extract comprising between about 1% and 20% of the composition, by weight; and
a Cinnamomum verum extract comprising between about 1% and 7% of the composition, by weight.
13 . A method of administering a composition, the method comprising:
administering a composition comprising one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, the composition further comprising:
a cannabidiol comprising between about 0.1% and 5% of the composition, by weight;
a Curcuma longa extract prepared with a dispersing agent comprising a carrier oil, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight:
a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight;
a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight;
a Schisandra chinensis extract comprising between about 1% and 20% of the composition, by weight; and
a Cinnamomum verum extract comprising between about 1% and 7% of the composition, by weight.